✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
No actionable change for audiologists; epilepsy risk quantification in NF2 is a neurology-facing finding, though it reinforces the importance of multidisciplinary monitoring in NF2 patients seen in audiology clinics.
✦ Why It Matters ✦
Quantifying epilepsy burden in NF2 helps characterize the full neurological profile of patients who often present first to audiology, supporting better cross-specialty referral and counseling.
✦ Key Points ✦
- 01Propensity-matched retrospective study using the TriNetX real-world database.
- 02Estimates cumulative incidence of epilepsy specifically in NF2 patients.
- 03NF2 causes bilateral vestibular schwannomas and progressive hearing loss; epilepsy is a lesser-studied comorbidity.
- 04No abstract was available; findings and sample size are not fully extractable.
- 05Published in Journal of the American Academy of Dermatology (doi: 10.1016/j.jaad.2026.07.107).
✦ Claims & Evidence ✦
ClaimEvidenceSupport
NF2 patients have a quantifiable cumulative incidence of epilepsy estimable via propensity-matched retrospective analysis.
studypartially supported✦ Research metadata ✦
- PMID
- 42556742
- DOI
- 10.1016/j.jaad.2026.07.107.
- Journal
- Journal of the American Academy of Dermatology
- Publication type
- research_article
- Evidence level
- 3
- Population
- Patients with Neurofibromatosis Type 2
- Intervention
- NF2 diagnosis (exposure)
- Comparator
- Propensity-matched patients without NF2
Primary outcomes
Cumulative incidence of epilepsy in NF2 patients